|Bid||109.28 x 1300|
|Ask||109.48 x 900|
|Day's range||108.99 - 110.16|
|52-week range||63.01 - 116.81|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||108.88|
|Earnings date||28 Jan 2020|
|Forward dividend & yield||0.80 (0.72%)|
|Ex-dividend date||10 Dec 2019|
|1y target est||125.20|
CONMED Corporation (NASDAQ: CNMD) today announced that it will report financial results for the fourth quarter and full year 2019 after the market close on Wednesday, January 29, 2020. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.
CONMED Corporation (NASDAQ: CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Monday, January 13, 2020 in San Francisco, CA.
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.